DUSSELDORF, Germany – BIO-Europe Fall 2011 entered its final day as Europe's financial system teetered on the brink – yet again – following Greece's shock decision to put its recently agreed bailout package to a popular vote. Although the issues facing Europe's biotechnology industry seem pretty minor in comparison, a definite sense of gloom has pervaded many of the discussions here at BIO-Europe.For all but the chosen few who have secured the best investment deals and the juiciest alliances, conditions are far from ideal.
DUSSELDORF, Germany – Buoyed by Monday's series of workshops on the dos and don'ts of finding partners and striking deals (and learning to live with them afterward), companies attending BIO-Europe Fall 2011 rolled up their sleeves Tuesday and started in on what they had really come for: bare knuckles partnering. With 14,661 scheduled one-to-one meetings – and countless more unscheduled, impromptu exchanges – it's unlikely that any aspect of biotechnology will not receive an airing at this event.
Biotie Therapies Oyj has closed the door on its proposed stock-based acquisition of Newron Pharmaceuticals SpA, following Merck Serono SA's surprise decision to exit a partnership with Newron on the Parkinson's drug safinamide.
DUSSELDORF, Germany – Golden autumn sunlight breaking over the mighty Rhine was the pleasing sight for delegates taking a breather from the many sessions at the BIO-Europe Fall 2011 meeting, which opened at the Congress Center Dusseldorf Monday.But there was little time to savor the view. With 2,825 individual delegates representing 1,596 companies in attendance, and 183 company presentations scheduled here through Wednesday, the meeting does not allow much time for hanging around.
DUSSELDORF, Germany – Buoyed by Monday's series of workshops on the dos and don'ts of finding partners and striking deals (and learning to live with them afterward), companies attending BIO-Europe Fall 2011 rolled up their sleeves Tuesday and started in on what they had really come for: bare knuckle partnering. With 14,661 scheduled one-to-one meetings – and countless more unscheduled, impromptu exchanges – it's unlikely that any aspect of biotechnology will not receive an airing at this event.
Underlining both the general volatility in the wider public markets and the specific uncertainties attaching to the FDA's present treatment of new drug applications for antibiotics, Arpida AG hit a 52-week low on news that it had completed a regulatory filing for Iclaprim, a synthetic diaminopyrimidine in development for treating complicated skin and skin structure infections (cSSSI). (BioWorld Today)
DUSSELDORF, Germany – Golden autumn sunlight breaking over the mighty Rhine was the pleasing sight for delegates taking a breather from the many sessions at the BIO-Europe Fall 2011 meeting, which opened at the Congress Center Dusseldorf Monday.But there was little time to savor the view.
BioXell SpA grossed CHF57.8 million (US$46.3 million) in an initial public offering on the Swiss Stock Exchange in Zurich to fund ongoing clinical and preclinical development of its portfolio of six drug candidates. (BioWorld International)
